$JNJ News

Johnson & Johnson (JNJ) Stock Sees Modest Fair Value Lift After Analyst Target Increases

J&J’s biotech progress could punish its 2027 profit

Abbott Laboratories vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026?

Johnson & Johnson vs. Danaher: Which Healthcare Stock Looks Better Positioned Following Earnings?

Johnson & Johnson Shares Edge Higher as $3.5B Biotech Moves Expand Oncology Pipeline

Is Wall Street Bullish or Bearish on Johnson & Johnson Stock?

J&J ventures further into in vivo CAR-T space with Sail partnership, potential buyout

Johnson & Johnson embarks on supply chain restructuring

Johnson & Johnson Just Got FDA Clearance for Its Surgical Robot, Hiked Its Dividend for the 64th Time, and Is Targeting $100 Billion in Revenue. But Here's What Investors Should Be Most Excited About

Johnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer

J&J nabs option to buy ‘in vivo’ CAR-T maker Sail for nearly $2.6B

Johnson & Johnson Advances Cancer and Immunology Treatments With Major Biotech Deals

Johnson & Johnson (JNJ) Seeks $5.5 Billion Talc Lawsuit Settlement

Johnson & Johnson Completes Acquisition of Firefly Bio, Inc. to Advance Next-Generation Oncology Innovation

Johnson & Johnson Announces Collaboration with Sail Biomedicines to Advance in vivo CAR-T Programs and Transform Autoimmune Disease Through Immune Reset

Johnson & Johnson Partners With Sail Biomedicines On In Vivo CAR-T Therapies, Secures $2.58B Acquisition Option; To Invest $785M In Sail, Expects The Agreements To Dilute Adjusted Operational Earnings Per Share And Adjusted Earnings Per Share By ~$0.18 In 2026 And ~$1.28 In 2027

Johnson & Johnson Says 2026 Adj Operational EPS And Adj EPS Expected To Decrease By $0.64; 2027 Adj Operational EPS And Adj EPS Expected To Decrease By $1.36

These 3 Companies Reported Record Results and Raised Guidance

Johnson & Johnson (JNJ) Stock May Be 31% Undervalued As Myeloma Trial Results Impress

Johnson & Johnson agrees to pay $5.5B to settle talc lawsuits